23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort

Clicks: 249
ID: 271968
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
23-Valent pneumococcal polysaccharide vaccine was previously reported to be ineffective in HIV-infected Ugandan adults. Prolonged follow-up of trial participants confirmed persistent excess of all-cause pneumonia in vaccine recipients [hazard ratio (HR) 1.6; 95% confidence interval (CI) 1.0-2.4], bu …
Reference Key
c2004aids23-valent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Watera C;Nakiyingi J;Miiro G;Muwonge R;Whitworth JA;Gilks CF;French N;;
Journal aids (london, england)
Year 2004
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/15166540
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult randomized controlled trials as topic regression analysis follow-up studies hiv infections / complications* uganda / epidemiology Cohort Studies pneumonia aids-related opportunistic infections / complications viral / mortality neil french pneumococcal vaccines* hiv infections / mortality viral / prevention & control* viral / complications aids-related opportunistic infections / prevention & control* aids-related opportunistic infections / mortality pmid:15166540 doi:10.1097/00002030-200405210-00018 christine watera jessica nakiyingi

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.